<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940691</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1510</org_study_id>
    <nct_id>NCT02940691</nct_id>
  </id_info>
  <brief_title>Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs</brief_title>
  <acronym>DARLO-C</acronym>
  <official_title>A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use or Receiving Opioid Substitution Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess
      whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus
      (HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who
      inject drugs (PWID) with recent injecting drug use or people receiving opioid substitution
      therapy and chronic HCV genotype 1 or 4 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, observational cohort design will be used to enrol patients attending tertiary,
      drug and alcohol and primary health care services in Sydney, Australia.

      The study consists of a treatment phase (12 weeks) and a follow-up phase (up to 3 years)
      where participants will be followed every 3 months for the first year and every 6 months in
      years 2-3 to evaluate treatment response and reinfection.

      The effectiveness of the treatment will be assessed by looking at the proportion of patients
      with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following therapy with
      grazoprevir/elbasvir and evaluate demographic and clinical predictors of non-response.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment due to new treatments becoming available.
  </why_stopped>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12)</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Number with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following 12 weeks of daily grazoprevir/elbasvir (100mg/50mg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Completion</measure>
    <time_frame>12 weeks from treatment administration</time_frame>
    <description>Number who completed HCV treatment as prescribed (12 weeks of grazoprevir/elbasvir (100mg/50mg) daily)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (Negative HCV RNA at the End of Treatment)</measure>
    <time_frame>12 weeks from treatment administration</time_frame>
    <description>Number with undetectable HCV RNA at end of treatment following 12 weeks of daily Grazoprevir/Elbasvir (100mg/50mg)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity and Specificity of the Finger-stick Xpert® HCV Viral Load Assay for HCV RNA Detection</measure>
    <time_frame>12 week post treatment</time_frame>
    <description>To determine the sensitivity and specificity of the Xpert® HCV Viral Load assay for HCV RNA detection in samples collected by finger-stick capillary whole-blood.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Grazoprevir/elbasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir/elbasvir</intervention_name>
    <description>Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.</description>
    <arm_group_label>Grazoprevir/elbasvir</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants have voluntarily signed the informed consent form.

          -  Be ≥18 years of age on day of signing informed consent form.

          -  Have chronic HCV genotype 1 or 4 infection (defined as detectable HCV RNA).

          -  Recent injecting drug use (previous 6 months) or receiving opioid substitution
             therapy.

          -  HIV-1 infected subjects enrolled in the study must meet the following criteria:

               -  Have HIV infection documented by any licensed rapid HIV test or HIV enzyme or
                  chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry
                  (Baseline) and confirmed by a licensed Western blot or a second antibody test by
                  a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 p24 antigen,
                  or plasma HIV-1 RNA viral load

               -  b) Be on HIV Antiretroviral Therapy (ART) for at least 4 weeks prior to study
                  entry using an ART regimen that is allowable with the intended DAA regimen as
                  determined by the current PI and the Liverpool drug interaction website
                  (http://www.hiv-druginteractions.org/) or current prescribing guidelines for
                  elbasvir/grazoprevir OR be naive to treatment with any antiretroviral therapy
                  (ART) with a baseline CD4 count of &gt;200 and have no plans to initiate ART
                  treatment while participating in this study and through to at least Follow-up
                  Week 4.

          -  Negative pregnancy test at screening and baseline (females of childbearing potential
             only).

          -  All fertile males and females must be using effective contraception during treatment
             and during 14 days after treatment end.

        Exclusion Criteria:

          -  Is taking or plans to take any prohibited medications as per DAA Product Information
             or herbal supplements, including but not limited to St. John's Wort (Hypericum
             perforatum) within 2 weeks of Baseline.

          -  Is currently using or intends to use barbiturates.

          -  Is a female and is pregnant or breast-feeding, or expecting to conceive or donate eggs
             from Baseline and continue throughout treatment, and after the last dose of study
             medication (as per the regimen requirements), or longer if dictated by local
             regulations.

          -  Has any condition or pre-study laboratory abnormality, ECG abnormality or history of
             any illness, which, in the opinion of the investigator, might confound the results of
             the study or pose additional risk in administering the study drugs to the subject.

          -  Had a life-threatening SAE during the screening period.

          -  Has exclusionary laboratory values as listed below:

               -  Haemoglobin &lt; 9.5 g/dL for both males and females

               -  Platelets &lt; 50 x 10^3 /µL

               -  Serum albumin &lt; 3.0 g/dL

          -  Patients with Child Pugh-B or C decompensated cirrhosis

          -  Previous HCV treatment-experience.

          -  Ongoing severe psychiatric disease as judged by the treating physician.

          -  Frequent injecting drug use that is judged by the treating physician to compromise
             treatment safety.

          -  Inability or unwillingness to provide informed consent or abide by the requirements of
             the study.

          -  Is Hepatitis B surface antigen (HBsAg) positive

        NOTE: Sanger sequencing will be performed on a pre-treatment sample on all participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Dore, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kirketon Road Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Langton Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug and Alcohol Clinical Services (Hunter)</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2300</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <results_first_submitted>August 19, 2019</results_first_submitted>
  <results_first_submitted_qc>December 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2019</results_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK-5172</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02940691/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Grazoprevir/Elbasvir</title>
          <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Grazoprevir/Elbasvir</title>
          <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>≤46 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;46 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Income</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Full time employment</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Part time employment</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Disability/social services</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any non-injecting drug use in the previous month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any injecting drug use in the previous month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any alcohol use in the previous month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hazardous alcohol use in the previous month</title>
          <description>Hazardous alcohol consumption is defined as a score of 3 or more for women and 4 or more for men on the Alcohol Use Disorders Identification Test (AUDIT-C).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of opioid substitution therapy (OST)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current opioid substitution therapy (OST)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C virus (HCV) genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1a</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1b</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of liver disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No or mild fibrosis (F0-F1)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or advanced fibrosis (F2-F3)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cirrhosis (F4)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12)</title>
        <description>Number with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following 12 weeks of daily grazoprevir/elbasvir (100mg/50mg)</description>
        <time_frame>12 weeks post treatment</time_frame>
        <population>All enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir/Elbasvir</title>
            <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12)</title>
          <description>Number with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following 12 weeks of daily grazoprevir/elbasvir (100mg/50mg)</description>
          <population>All enrolled</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>SVR12</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No test performed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lost to follow-up</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Incarcerated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Completion</title>
        <description>Number who completed HCV treatment as prescribed (12 weeks of grazoprevir/elbasvir (100mg/50mg) daily)</description>
        <time_frame>12 weeks from treatment administration</time_frame>
        <population>All enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir/Elbasvir</title>
            <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Completion</title>
          <description>Number who completed HCV treatment as prescribed (12 weeks of grazoprevir/elbasvir (100mg/50mg) daily)</description>
          <population>All enrolled</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Treatment completion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lost to follow-up</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Incarcerated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End of Treatment Response (Negative HCV RNA at the End of Treatment)</title>
        <description>Number with undetectable HCV RNA at end of treatment following 12 weeks of daily Grazoprevir/Elbasvir (100mg/50mg)</description>
        <time_frame>12 weeks from treatment administration</time_frame>
        <population>Those who completed treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir/Elbasvir</title>
            <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>End of Treatment Response (Negative HCV RNA at the End of Treatment)</title>
          <description>Number with undetectable HCV RNA at end of treatment following 12 weeks of daily Grazoprevir/Elbasvir (100mg/50mg)</description>
          <population>Those who completed treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ETR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not tested</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sensitivity and Specificity of the Finger-stick Xpert® HCV Viral Load Assay for HCV RNA Detection</title>
        <description>To determine the sensitivity and specificity of the Xpert® HCV Viral Load assay for HCV RNA detection in samples collected by finger-stick capillary whole-blood.</description>
        <time_frame>12 week post treatment</time_frame>
        <population>Only 22 had both Xpert and plasma samples collected. Some participants had &gt;1 paired sample. HCV RNA from plasma was compared to the Xpert result. Sensitivity is number of positive Xpert results divided by the number of positive plasma results. The specificity is number of negative Xpert results divided by the number of negative plasma results.</population>
        <group_list>
          <group group_id="O1">
            <title>Xpert HCV VL Fingerstick</title>
            <description>Sensitivity and specificity of the Xpert HCV VL Fingerstick assay for HCV detection in capillary whole-blood samples collected via fingerstick compares with Aptima HCV Quant Dx perforomed on EDTA plasma stored at -80C collected via venepuncture.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of the Finger-stick Xpert® HCV Viral Load Assay for HCV RNA Detection</title>
          <description>To determine the sensitivity and specificity of the Xpert® HCV Viral Load assay for HCV RNA detection in samples collected by finger-stick capillary whole-blood.</description>
          <population>Only 22 had both Xpert and plasma samples collected. Some participants had &gt;1 paired sample. HCV RNA from plasma was compared to the Xpert result. Sensitivity is number of positive Xpert results divided by the number of positive plasma results. The specificity is number of negative Xpert results divided by the number of negative plasma results.</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="78.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not collected in the study. Only serious adverse events were collected from Screening through to 4 weeks post end of treatment</time_frame>
      <desc>The studied medication was registered in the country of use and the study used the medication according to the indication. As the toxicity profile of this regimen is well known including within the patient population in this study, adverse events were not collected. Drug was accessed via the government subsidized medications program. Any adverse drug reactions were reported to the government health authority as per standard practice for medications supplied through the government program.</desc>
      <group_list>
        <group group_id="E1">
          <title>Grazoprevir/Elbasvir</title>
          <description>Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration of arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Schizoaffective Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Drug-Induced Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Jason Grebely</name_or_title>
      <organization>Kirby Institute</organization>
      <phone>+61 2 9385 0957</phone>
      <email>jgrebely@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

